Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab

Conditions:   Non-Small Cell Lung Cancer;   Head and Neck Squamous Cell Carcinoma Interventions:   Drug: ABBV-514;   Drug: Pembrolizumab;   Drug: Budigalimab Sponsor:   AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials